Phase I study of docetaxel plus S-1 combination chemotherapy for recurrent non-small cell lung cancer

  • Authors:
    • Kazunori Fujitaka
    • Noboru Hattori
    • Tadashi Senoo
    • Hiroshi Iwamoto
    • Shinichiro Ohshimo
    • Masashi Kanehara
    • Nobuhisa Ishikawa
    • Yoshinori Haruta
    • Hiroshi Murai
    • Nobuoki Kohno
  • View Affiliations

  • Published online on: November 23, 2010     https://doi.org/10.3892/ol.2010.218
  • Pages: 167-170
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

S-1 is a novel oral fluorouracil prodrug that plays a role in non-small cell lung cancer (NSCLC). Docetaxel (DTX) is one of the standard agents for relapsed NSCLC. We performed a phase I study of DTX plus S-1 combination therapy as second-line treatment for NSCLC to determine the maximum tolerated dose (MTD) and recommended dose (RD). Patients with recurrent NSCLC, aged 20-74 years with an Eastern Cooperative Oncology Group performance status of 0-1 and measurable lesions, were enrolled. The treatment consisted of four dose levels. The patients received DTX (40-60 mg/m2 intravenously on day 1) and S-1 (65-80 mg/m2 orally, daily on days 1-14) for each 21-day cycle. Three to six patients were treated at each dose level with the two drugs, with MTD defined as the dose level at which dose-limiting toxicity (DLT) occurred in 33% of the patients. A total of 17 patients were enrolled. At dose level 4 (DTX, 60 mg/m2; S-1, 80 mg/m2) 3 of 5 patients experienced DLT and this level was regarded as the MTD. Therefore, dose level 3 (DTX, 60 mg/m2; S-1, 65 mg/m2) was selected as the RD for subsequent studies. The DLTs were neutropenia (grade 4) and mucositis (grade 3). The response rate was 5.9% (1 of 17 patients achieved a partial response) and 14 of 17 patients achieved stable disease. This combination regimen showed a tolerable and manageable profile in recurrent NSCLC and therefore warrants further evaluation.
View References

Related Articles

Journal Cover

January-February 2011
Volume 2 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Fujitaka K, Hattori N, Senoo T, Iwamoto H, Ohshimo S, Kanehara M, Ishikawa N, Haruta Y, Murai H, Kohno N, Kohno N, et al: Phase I study of docetaxel plus S-1 combination chemotherapy for recurrent non-small cell lung cancer. Oncol Lett 2: 167-170, 2011
APA
Fujitaka, K., Hattori, N., Senoo, T., Iwamoto, H., Ohshimo, S., Kanehara, M. ... Kohno, N. (2011). Phase I study of docetaxel plus S-1 combination chemotherapy for recurrent non-small cell lung cancer. Oncology Letters, 2, 167-170. https://doi.org/10.3892/ol.2010.218
MLA
Fujitaka, K., Hattori, N., Senoo, T., Iwamoto, H., Ohshimo, S., Kanehara, M., Ishikawa, N., Haruta, Y., Murai, H., Kohno, N."Phase I study of docetaxel plus S-1 combination chemotherapy for recurrent non-small cell lung cancer". Oncology Letters 2.1 (2011): 167-170.
Chicago
Fujitaka, K., Hattori, N., Senoo, T., Iwamoto, H., Ohshimo, S., Kanehara, M., Ishikawa, N., Haruta, Y., Murai, H., Kohno, N."Phase I study of docetaxel plus S-1 combination chemotherapy for recurrent non-small cell lung cancer". Oncology Letters 2, no. 1 (2011): 167-170. https://doi.org/10.3892/ol.2010.218